Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CARsgen Therapeutics Holdings Ltd. (HK:2171)
:2171
Holding HK:2171?
Track your performance easily
2171 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$2.48 - HK$11.78
Previous CloseN/A
Volume4.65M
Average Volume (3M)11.32M
Market Cap
HK$6.11B
Enterprise ValueHK$1.13B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Mar 18, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding571,670,900
10 Day Avg. Volume8,185,400
30 Day Avg. Volume11,315,861
Standard Deviation0.26
R-Squared0.11
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)286.21
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CARsgen Therapeutics Holdings Ltd. News
PremiumCompany Announcements
CARsgen Reports Positive Trial Results for Cancer TherapyPremiumCompany Announcements
CARsgen Strengthens Financial Oversight with New Audit Committee
PremiumCompany Announcements
CARsgen Showcases Promising CAR T-Cell Therapy Advances
PremiumCompany Announcements
CARsgen Therapeutics Grants Share Options to EmployeesPremiumCompany Announcements
CARsgen’s FDA Clearance Boosts Cancer Therapy Prospects
PremiumCompany Announcements
CARsgen to Showcase CAR T-cell Innovations at ASH 2024
PremiumCompany Announcements
CARsgen Therapeutics Seeks FDA Approval AdvancementOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.79% Mutual Funds
― Other Institutional Investors
97.10% Public Companies and
Individual Investors
2171 FAQ
What was CARsgen Therapeutics Holdings Ltd.’s price range in the past 12 months?
CARsgen Therapeutics Holdings Ltd. lowest stock price was HK$2.48 and its highest was HK$11.78 in the past 12 months.
What is CARsgen Therapeutics Holdings Ltd.’s market cap?
CARsgen Therapeutics Holdings Ltd.’s market cap is HK$6.11B.
When is CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date?
CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date is Mar 18, 2025 which is in 58 days.
How were CARsgen Therapeutics Holdings Ltd.’s earnings last quarter?
CARsgen Therapeutics Holdings Ltd. released its earnings results on Aug 28, 2024. The company reported -HK$0.67 earnings per share for the quarter, missing the consensus estimate of -HK$0.276 by -HK$0.393.
Is CARsgen Therapeutics Holdings Ltd. overvalued?
According to Wall Street analysts CARsgen Therapeutics Holdings Ltd.’s price is currently Overvalued.
Does CARsgen Therapeutics Holdings Ltd. pay dividends?
CARsgen Therapeutics Holdings Ltd. does not currently pay dividends.
What is CARsgen Therapeutics Holdings Ltd.’s EPS estimate?
CARsgen Therapeutics Holdings Ltd.’s EPS estimate is -0.43.
How many shares outstanding does CARsgen Therapeutics Holdings Ltd. have?
CARsgen Therapeutics Holdings Ltd. has 571,670,900 shares outstanding.
What happened to CARsgen Therapeutics Holdings Ltd.’s price movement after its last earnings report?
CARsgen Therapeutics Holdings Ltd. reported an EPS of -HK$0.67 in its last earnings report, missing expectations of -HK$0.276. Following the earnings report the stock price went down -0.824%.
Which hedge fund is a major shareholder of CARsgen Therapeutics Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2171
---
CARsgen Therapeutics Holdings Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.89%
12-Months-Change
Fundamentals
Return on Equity
-37.70%
Trailing 12-Months
Asset Growth
-20.83%
Trailing 12-Months
Company Description
CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd is primarily engaged in discovering, developing, and commercializing innovative cell therapies in China and the...
---
Technical Analysis
Akeso, Inc.
―
CanSino Biologics, Inc. Class H
―
Viva Biotech Holdings
―
EC Healthcare
―
---